Biopharmaceuticals provide a valuable new approach to disease management. But a significant limitation in their use is the development of anti-drug antibodies (ADA) in some patients. The development of ADA is seen to some extent across all diseases and with all treatments, but the individual data sets for any single disease and treatment have usually been small. ABIRISK seeks to bring these data sets together to understand the common underlying causes of ADA. To do this, disparate data sets from multiple disease areas and many different institutions need to be analysed together. These data can be decades old and drawn from all corners of Europe using a wide range of clinical techniques and standards. They must then be combined with new data from studies commissioned by ABIRISK themselves. ABIRISK needs to bring these data together in such a way that common factors can be identified.
Together ABIRISK and eTRIKS have set up a jointly managed environment in which the data from the ABIRISK partners can be quality checked, standardised to ensure it is compatible, curated into a standard data tree and loaded into the latest version of tranSMART to allow novel analyses across disease areas. In addition to ground breaking research, this collaboration is also leading the way in establishing the legal framework in which IMI projects can work together effectively.